Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;21(1):14-23.
doi: 10.17925/EE.2025.21.1.1. Epub 2025 Feb 7.

Efficacy and Safety of Early Initiation of Sodium-Glucose Co-transporter-2 Inhibitors Following Acute Myocardial Infarction: A Systematic Review and Meta-analysis

Deep Dutta  1 , Lakshmi Nagendra  2 , Abm Kamrul-Hasan  3 , Kunal Mahajan  4
Affiliations

Efficacy and Safety of Early Initiation of Sodium-Glucose Co-transporter-2 Inhibitors Following Acute Myocardial Infarction: A Systematic Review and Meta-analysis

Deep Dutta et al. touchREV Endocrinol. 2025 May.

Abstract

Background: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are the preferred agents for managing type 2 diabetes in patients with established atherosclerotic cardiovascular disease and for reducing hospitalization for heart failure (HHF) in patients with heart failure with reduced and preserved ejection fraction. We undertook this meta-analysis, as, to date, no meta-analysis has holistically analysed the potential benefits and safety of SGLT2i in patients with acute myocardial infarction (MI).

Methods: Electronic databases were searched for randomized controlled trials (RCTs) involving patients with MI who received SGLT2i in the intervention arm (initiated within 2 weeks of the index event) and placebo/active comparator in the control arm. The primary outcome was to evaluate the impact on cardiovascular death, all-cause death and HHF. The secondary outcomes were to evaluate the impact on echocardiographic parameters, N-terminal pro-b-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein, MI, stroke, all-cause hospitalization and safety issues.

Results: From initially screened 8,922 articles, data from 6 RCTs were analysed (7,409 patients). Early initiation of SGLT2i following MI was associated with significantly lower future HHF (odds ratio [OR]: 0.75; 95% confidence interval [CI]: 0.62-0.90; p=0.002; I 2=0%) and significantly higher left-ventricular ejection fraction (mean difference [MD]: 1.65%; 95% CI: 0.34-2.96; p=0.01; I 2=0%) compared with placebo. Compared with placebo, SGLT2i following MI had no beneficial impact on cardiovascular deaths (OR: 1.04; 95% CI: 0.83-1.30; p=0.76; I 2=0%), all-cause mortality (OR: 1.00; 95% CI: 0.82-1.21; p=0.98; I 2=0%), stroke (OR: 0.58; 95% CI: 0.26-1.27; p=0.17), all-cause hospitalization (OR: 1.13; 95% CI: 0.97-1.32; p=0.11; I 2=0%) and percentage change in NT-proBNP (MD: 1.18%; 95% CI: -9.78 to 12.14; p=0.83; I 2=52%). SGLT2i were well tolerated without increased ketoacidosis, acute renal failure or hepatic injury.

Conclusion: Early initiation of SGLT2i in acute MI is safe, well tolerated and associated with a reduction in HHF.

Keywords: Dapagliflozin; empagliflozin; meta-analysis; myocardial infarction; safety; sodium–glucose co-transporter-2 inhibitor.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Deep Dutta, Lakshmi Nagendra, ABM Kamrul Hasan and Kunal Mahajan have no financial or non-financial relationships or activities to declare in relation to this article.

Figures

Figure 1:
Figure 1:. Forest plot highlighting the impact of early initiation of sodium–glucose co-transporter-2 inhibitors in patients with myocardial infarction
Figure 2:
Figure 2:. Forest plot highlighting the impact of early initiation of sodium–glucose co-transporter-2 inhibitors in patients with myocardial infarction
Figure 3:
Figure 3:. Forest plot highlighting the impact of early initiation of sodium–glucose co-transporter-2 inhibitors in patients with myocardial infarction
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Szummer K, Wallentin L, Lindhagen L et al. Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: Experiences from SWEDEHEART registry 1995 to 2014. Eur Heart J. 2018;39:3766–76. doi: 10.1093/eurheartj/ehy554. - DOI - PubMed
    1. McGuire DK, Shih WJ, Cosentino F et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis. JAMA Cardiol. 2021;6:148–58. doi: 10.1001/jamacardio.2020.4511. - DOI - PMC - PubMed
    1. Solomon SD, McMurray JJV, Claggett B et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089–98. doi: 10.1056/NEJMoa2206286. - DOI - PubMed
    1. Vaduganathan M, Docherty KF, Claggett BL et al. SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757–67. doi: 10.1016/S0140-6736(22)01429-5. - DOI - PubMed
    1. Anker SD, Butler J, Filippatos G et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–61. doi: 10.1056/NEJMoa2107038. - DOI - PubMed

Publication types

LinkOut - more resources